Risk factors for hepatitis C seropositivity among young people who inject drugs in New York City: Implications for prevention

PLoS ONE

Volumn 12, Issue 5, 2017, Pages

  Eckhardt, Benjamin ^a   Winkelstein, Emily R ^b   Shu, Marla A ^b,c   Carden, Michael R ^b   McKnight, Courtney ^c   Des Jarlais, Don C ^c   Glesby, Marshall J ^a   Marks, Kristen ^a   Edlin, Brian R ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NATIONAL DEVELOPMENT AND RESEARCH INSTITUTES   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS C ANTIBODY; ILLICIT DRUG;

ADULT; AGE; ARTICLE; CAUCASIAN; CROSS-SECTIONAL STUDY; DRUG USE; FEMALE; HEPATITIS C; HOMELESS PERSON; HUMAN; INFECTION PREVENTION; MALE; NAMED GROUPS OF PERSONS; NEW YORK; PEOPLE WHO INJECT DRUGS; RISK FACTOR; SEROPREVALENCE; SYRINGE; UNEMPLOYMENT; VIRUS TRANSMISSION; YOUNG ADULT; ADOLESCENT; BLOOD; COMPLICATION; NEEDLE SHARING; SUBSTANCE ABUSE; TRANSMISSION;

ADOLESCENT; ADULT; CROSS-SECTIONAL STUDIES; FEMALE; HEPATITIS C; HUMANS; MALE; NEEDLE SHARING; NEW YORK CITY; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; YOUNG ADULT;

EID: 85019393924     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0177341     Document Type: Article

References (40)

1. Klevens RM, Hu DJ, Jiles R, Holmberg SD. Evolving epidemiology of hepatitis C virus in the United States. Clin Infect Dis. United States; 2012; 55 Suppl 1: S3-9.
2. Ly KN, Hughes EM, Jiles RB, Holmberg SD. Rising Mortality Associated With Hepatitis C Virus in the United States, 2003-2013. Clin Infect Dis. 2016; https://doi.org/10.1093/cid/ciw111 PMID: 26936668
3. Tseng F-C, O'Brien TR, Zhang M, Kral AH, Ortiz-Conde BA, Lorvick J, et al. Seroprevalence of hepatitis C virus and hepatitis B virus among San Francisco injection drug users, 1998 to 2000. Hepatology. 2007; 46: 666-71. https://doi.org/10.1002/hep.21765 PMID: 17657818
4. Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health. UNITED STATES; 1996; 86: 655-661.
5. Lorvick J, Kral AH, Seal K, Gee L, Edlin BR. Prevalence and duration of hepatitis C among injection drug users in San Francisco, Calif. Am J Public Health. United States; 2001; 91: 46-47.
6. Thomas DL, Vlahov D, Solomon L, Cohn S, Taylor E, Garfein R, et al. Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore). UNITED STATES; 1995; 74: 212-220.
7. Tseng F-C, O'Brien TR, Zhang M, Kral AH, Ortiz-Conde BA, Lorvick J, et al. Seroprevalence of hepatitis C virus and hepatitis B virus among San Francisco injection drug users, 1998 to 2000. Hepatology. United States; 2007; 46: 666-671. https://doi.org/10.1002/hep.21765 PMID: 17657818
8. Hagan H, McGough JP, Thiede H, Weiss NS, Hopkins S, Alexander ER. Syringe exchange and risk of infection with hepatitis B and C viruses. Am J Epidemiol. UNITED STATES; 1999; 149: 203-213.
9. Bell J, Batey RG, Farrell GC, Crewe EB, Cunningham AL, Byth K. Hepatitis C virus in intravenous drug users. Med J Aust. AUSTRALIA: Westmead Hospital, NSW.; 1990; 153: 274-276.
10. Kwon JA, Anderson J, Kerr CC, Thein H-H, Zhang L, Iversen J, et al. Estimating the cost-effectiveness of needle-syringe programs in Australia. AIDS. England; 2012; 26: 2201-2210.
11. Edlin BR. Perspective: test and treat this silent killer. Nature. 2011/05/27 ed. 2011; 474: S18-9.
12. Thorpe LE. Risk of Hepatitis C Virus Infection among Young Adult Injection Drug Users Who Share Injection Equipment. Am J Epidemiol. 2002; 155: 645-653. https://doi.org/10.1093/aje/155.7.645 PMID: 11914192
13. Hahn JA, Page-Shafer K, Lum PJ, Bourgois P, Stein E, Evans JL, et al. Hepatitis C Virus Seroconversion among Young Injection Drug Users: Relationships and Risks. J Infect Dis. 2002; 186:1558-1564. https://doi.org/10.1086/345554 PMID: 12447730
14. Page K, Morris MD, Hahn JA, Maher L, Prins M. Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention. Clin Infect Dis. United States; 2013; 57 Suppl 2: S32-8.
15. Jordan AE, Des Jarlais DC, Arasteh K, McKnight C, Nash D, Perlman DC. Incidence and prevalence of hepatitis c virus infection among persons who inject drugs in New York City: 2006-2013. Drug Alcohol Depend. Ireland; 2015; 152:194-200.
16. Zibbell JE, Iqbal K, Patel RC, Suryaprasad A, Sanders KJ, Moore-Moravian L, et al. Increases in hepatitis C virus infection related to injection drug use among persons aged <30 years - Kentucky, Tennessee, Virginia, and West Virginia, 2006-2012. Frieden TR Cono J, Richards CL, Iademarco MF J HW, editor. MMWR Morb Mortal Wkly Rep. United States; 2015; 64: 453-458.
17. Peters PJ, Pontones P, Hoover KW, Patel MR, Galang RR, Shields J, et al. HIV Infection Linked to Injection Use of Oxymorphone in Indiana, 2014-2015. N Engl J Med. Massachusetts Medical Society; 2016; 375: 229-239. https://doi.org/10.1056/NEJMoa1515195 PMID: 27468059
18. Jones CM, Logan J, Gladden RM, Bohm MK, Author MPH. Vital Signs: Demographic and Substance Use Trends Among Heroin Users - United States, 2002-2013. MMWR Morb Mortal Wkly Rep. 2015; 64.
19. CDC Division of Viral Hepatitis. Viral Hepatitis Surveillance. 2014.
20. Suryaprasad AG, White JZ, Xu F, Eichler B-A, Hamilton J, Patel A, et al. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012. Clin Infect Dis. United States; 2014; 59:1411-1419. https://doi.org/10.1093/cid/ciu643 PMID: 25114031
21. Schulte M, Hser Y, Saxon A, Evans E, Li L, Huang D, et al. Risk Factors Associated with HCV Among Opioid-Dependent Patients in a Multisite Study. J Community Health. Netherlands; 2015; 40: 940-947.
22. Villano Sa, Vlahov D, Nelson KE, Lyles CM, Cohn S, Thomas DL. Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. J Clin Microbiol. 1997; 35: 3274-3277. PMID: 9399533
23. Hahn J a., Page-Shafer K, Lum PJ, Ochoa K, Moss a. R. Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. Hepatology. 2001; 34:180-187. https://doi.org/10.1053/jhep.2001.25759 PMID: 11431749
24. Diaz T, Des Jarlais DC, Vlahov D, Perlis TE, Edwards V, Friedman SR, et al. Factors associated with prevalent hepatitis C: Differences among young adult injection drug users in lower and upper Manhattan, New York City. Am J Public Health. 2001; 91: 23-30. https://doi.org/10.2105/AJPH.91.1.23 PMID: 11189819
25. Hagan H, Pouget ER, Des Jarlais DC. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. J Infect Dis. 2011; 204: 74-83. https://doi.org/10.1093/infdis/jir196 PMID: 21628661
26. NYSDOH/AIDS Institute - Harm Reduction Unit. NYS-Authorized Syringe Exchange Programs. 2015.
27. Tempalski B, Pouget ER, Cleland CM, Brady JE, Cooper HLF, Hall HI, et al. Trends in the Population Prevalence of People Who Inject Drugs in US Metropolitan Areas 1992-2007. 2013; 8. https://doi.org/10.1371/journal.pone.0064789 PMID: 23755143
28. Edlin BR, Shu M a., Winkelstein E, Des Jarlais DC, Busch MP, Rehermann B, et al. More Rare Birds, and the Occasional Swan. Gastroenterology. AGA Institute American Gastroenterological Association; 2009; 136: 2412-2414. https://doi.org/10.1053/j.gastro.2009.04.040 PMID: 19414076
29. Mateu-Gelabert P, Guarino H, Jessell L, Teper A. Injection and sexual HIV/HCV risk behaviors associated with nonmedical use of prescription opioids among young adults in New York City. J Subst Abuse Treat. United States; 2015; 48:13-20.
30. Mihailovic A, Tobin K, Latkin C. The influence of a peer-based HIV prevention intervention on conversation about HIV prevention among people who inject drugs in Baltimore, Maryland. AIDS Behav. United States; 2015; 19:1792-1800. https://doi.org/10.1007/s10461-015-1048-4 PMID: 25845530
31. Coyle SL, Needle RH, Normand J. Outreach-based HIV prevention for injecting drug users: a review of published outcome data. Public Health Rep. UNITED STATES; 1998; 113 Suppl 1:19-30.
32. Seal KH, Thawley R, Gee L, Bamberger J, Kral AH, Ciccarone D, et al. Naloxone distribution and cardiopulmonary resuscitation training for injection drug users to prevent heroin overdose death: a pilot intervention study. J Urban Health. United States; 2005; 82: 303-311. https://doi.org/10.1093/jurban/jti053 PMID: 15872192
33. Morano JP, Gibson BA, Altice FL. The Burgeoning HIV/HCV Syndemic in the Urban Northeast: HCV, HIV, and HIV/HCV Coinfection in an Urban Setting. PLoS One. 2013; 8:1-12. https://doi.org/10.1371/journal.pone.0064321 PMID: 23691197
34. Thorpe LE, Ouellet LJ, Levy JR, Williams IT. Hepatitis C Virus Infection: Prevalence, Risk Factors, and Prevention Opportunities among Young Injection Drug Users in Chicago, 1997-1999. 1999; 1997-1999.
35. Pouget ER, McKnight C, Des Jarlais DC, Hagan H. Housing instability and hepatitis C seroconversion among injection drug users: A meta-analytic review. APHA 139th Annual Meeting and Exposition. Washington DC; 2011. p. #246814.
36. Foderaro L. Ithaca's Anti-Heroin Plan: Open a Site to Shoot Heroin. New York Times. 2016: A1.
37. Marshall BD, Milloy MJ, Wood E, Montaner JS, Kerr T. Reduction in overdose mortality after the opening of North America's first medically supervised safer injecting facility: A retrospective population-based study. Lancet. Elsevier Ltd; 2011; 377:1429-1437. https://doi.org/10.1016/S0140-6736(10)62353-7
38. Potier C, Laprévote V, Dubois-Arber F, Cottencin O, Rolland B. Supervised injection services: What has been demonstrated? A systematic literature review. Drug Alcohol Depend. 2014; 145:48-68. https://doi.org/10.1016/j.drugalcdep.2014.10.012 PMID: 25456324
39. Strathdee SA, Arredondo J, Rocha T, Abramovitz D, Rolon ML, Patiño Mandujano E, et al. A police education programme to integrate occupational safety and HIV prevention: protocol for a modified stepped-wedge study design with parallel prospective cohorts to assess behavioural outcomes. BMJ Open. 2015; 5: e008958. https://doi.org/10.1136/bmjopen-2015-008958 PMID: 26260350
40. Beletsky L, Grau LE, White E, Bowman S, Heimer R. Prevalence, characteristics, and predictors of police training initiatives by US SEPs: Building an evidence base for structural interventions. Drug Alcohol Depend. Elsevier Ireland Ltd; 2011; 119:145-149. https://doi.org/10.1016/j.drugalcdep.2011.05.034 PMID: 21705159